Abeona Therapeutics Gets Rare Pediatric Disease Designation

Abeona Therapeutics Gets Rare Pediatric Disease Designation

Abeona Therapeutics said early Tuesday that the US Food and Drug Administration has grated a rare pediatric disease designation to its EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa, including recessive dystrophic epidermolysis bullosa, which are life-threatening genetic skin disorders characterized by skin blisters and erosions that cover the body. With this designation, the FDA may give the company a pediatric priority review voucher if the drug is […]

Read More ˃